NEWTOWN SQUARE, Pa., June 16, 2015 /PRNewswire/ -- The most prestigious and highly acclaimed annual event of the BIO-2015 is being held in Philadelphia – June 15-18. This International Convention is hosted by the Biotechnology Industry Organization (http://convention.bio.org/about-bio-convention/ ). Kibow Biotech, Inc. is pleased to announce their continued participation as an exhibitor along with several other Pennsylvania companies in the PA State Pavilion exhibition booth at the PA Convention Center, Philadelphia.
The company's flagship product Renadyl™, developed with a pharma like validation over a decade, is currently marketed online through the company websites (www.renadyl.com or www.kibow.com). Kibow Biotech is a pioneering R&D Biotech company involved in novel and niche application of probiotics and prebiotics in modulation or stabilization of Gut Microbiome towards Kidney health applications worldwide. Renadyl™ is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology known as ENTERIC DIALYSIS®.
With the recent rapid technological advances and knowledge gained in the fast emerging field of GUT MICROBIOME, it is evident that microbial therapy will soon be heading to the clinic. In this regard, Kibow's ENTERIC DIALYSIS® is ideally positioned to diversify and move forward with its strategy of a drug therapy pathway towards pre-dialysis and dialysis - Chronic Kidney Disease (CKD) applications. This may be accelerated with the newer end points based upon the reduction of GFR for CKD patient clinical trials which has gained acceptance both from US FDA and National Kidney Foundation (NKF) authorities, (http://www.medscape.com/viewarticle/836361).
Kibow is seeking to advance its supplement, currently with 20 patents US and globally, to a drug category following US FDA's expedited drug approval process in collaboration with a major pharma or biotech company via the BIO One-on-One Partnering system (http://convention.bio.org/partnering_old.aspx). BIO's One-on-One Partnering system is an efficient way to initially explore and identify business partnerships at the largest venue for mutual collaboration between interested parties.
About Kibow Biotech: Established in 1997, Kibow Biotech specializes in research and development of probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to the governmental rules and regulatory authorities of individual countries.
About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®":
Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol SA) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.